
A study of 1,068 adults found whole-blood NAD fell in those with cardiovascular disease and hypertension but did not decline with age.
Ratherthan shortening the hospital stay and improving clinical outcomes, a 48-hour infusion of milrinone was associated with increased early treatment failure-particularly due to the development of arrhythmias and hypotension-in patients hospitalized with acute exacerbations of chronic heart failure (CHF).